{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:12:11Z","timestamp":1788455531635,"version":"build-2803163510"},"reference-count":116,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education","doi-asserted-by":"publisher","award":["075-15-2019-1665"],"award-info":[{"award-number":["075-15-2019-1665"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Ebola virus disease (EVD) is an acute illness with a high-case fatality rate (CFR) caused by an RNA virus belonging to the Filoviridae family. Over the past 50 years, regular EVD outbreaks have been reported. The West African EVD outbreak of 2013\u20132016 proved to be significantly more widespread and complex than previous ones, resulting in approximately 11,000 deaths. A coordinated international effort was required to bring the outbreak under control. One of the main challenges faced by clinicians and researchers combating EVD was the absence of vaccines and preventive treatments. Only recently have efforts led to the development of effective therapeutic options. Among these, monoclonal antibody-based drugs have emerged as the most promising agents for the urgent treatment of EVD. This article aims to review the key milestones in the development of antibody-based therapies for EVD, tracing the journey from the use of convalescent serum to the creation of effective monoclonal antibody-based drugs and their combinations.<\/jats:p>","DOI":"10.3390\/antib14010022","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T03:18:22Z","timestamp":1741144702000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-4453","authenticated-orcid":false,"given":"Dmitriy N.","family":"Shcherbakov","sequence":"first","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo 630559, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya A.","family":"Isaeva","sequence":"additional","affiliation":[{"name":"State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo 630559, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2185-3515","authenticated-orcid":false,"given":"Egor A.","family":"Mustaev","sequence":"additional","affiliation":[{"name":"Department of Natural Sciences, Novosibirsk State University, Pirogova st., 2, Novosibirsk 630090, Russia"},{"name":"Synchrotron Radiation Facility\u2014Siberian Circular Photon Source \u201cSKlF\u201d Boreskov Institute of Catalysis of Siberian Branch of the Russian Academy of Sciences, Nikolskiy pr-t, 1, Koltsovo 630559, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1414992","article-title":"West African Ebola epidemic after one year\u2014Slowing but not yet under control","volume":"372","author":"Ariyarajah","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/22221751.2023.2239950","article-title":"Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Ta\u00ef Forest virus infection","volume":"12","author":"Fletcher","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1099\/vir.0.019794-0","article-title":"Characterization of the Ebola virus nucleoprotein\u2013RNA complex","volume":"91","author":"Noda","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/JVI.77.3.1793-1800.2003","article-title":"Biochemical and functional characterization of the Ebola virus VP24 protein: Implications for a role in virus assembly and budding","volume":"77","author":"Han","year":"2003","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/imt.13.124","article-title":"An update on the use of antibodies against the filoviruses","volume":"5","author":"Saphire","year":"2013","journal-title":"Immunotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","article-title":"Processing of the Ebola virus glycoprotein by the proprotein convertase furin","volume":"95","author":"Volchkov","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jmb.2007.10.017","article-title":"Complex of a protective antibody with its ebola virus GP peptide epitope: Unusual features of a V\u03bbx light chain","volume":"375","author":"Lee","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0092-8674(00)81248-9","article-title":"Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses","volume":"85","author":"Gallaher","year":"1996","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0025727300001198","article-title":"Emil Behring\u2019s Medical Culture: From Disinfection to Serotherapy","volume":"51","author":"Simon","year":"2007","journal-title":"Med. Hist."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40409-015-0003-1","article-title":"Post-exposure treatment of Ebola virus using passive immunotherapy: Proposal for a new strategy","volume":"21","author":"Chippaux","year":"2015","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/bmj.2.6086.541","article-title":"A case of Ebola virus infection","volume":"2","author":"Emond","year":"1977","journal-title":"Br. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1086\/514311","article-title":"Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: Determinants of survival","volume":"179","author":"Sadek","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea","volume":"374","author":"Delamou","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"91","article-title":"Polucheniye giperimmunnoy loshadinoy syvorotki k virusu Ebola","volume":"40","author":"Krasnyanskiy","year":"1994","journal-title":"Vopr. Virusol."},{"key":"ref_16","first-page":"82","article-title":"Otsenka na pavianakh-gamadrilakh vozmozhnosti spetsificheskoy profilaktiki likhoradki Ebola","volume":"39","author":"Mikhaylov","year":"1994","journal-title":"Vopr. Virusol."},{"key":"ref_17","first-page":"270","article-title":"Razrabotka i izucheniye svoystv immunoglobulinov protiv likhoradki Ebola","volume":"40","author":"Borisevich","year":"1995","journal-title":"Vopr. Virusol."},{"key":"ref_18","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch. Virol. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/514310","article-title":"Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections","volume":"179","author":"Jahrling","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_20","first-page":"98","article-title":"Virus specific antibody\u2014Based remedies for the urgent prevention and treatment of Ebola virus disease","volume":"91","author":"Sizikova","year":"2019","journal-title":"Ter. Arkhiv"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zheng, X., Wong, G., Zhao, Y., Wang, H., He, S., Bi, Y., Chen, W., Jin, H., Gai, W., and Chu, D. (2016). Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Sci. Rep., 6.","DOI":"10.1038\/srep24179"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"4","author":"Keller","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/infdis\/jiv565","article-title":"Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection","volume":"213","author":"Dowall","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dowall, S.D., Bosworth, A., Rayner, E., Taylor, I., Landon, J., Cameron, I., Coxon, R.I., Al-Abdulla, I., Graham, V.A., and Hall, G. (2016). Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci. Rep., 6.","DOI":"10.1038\/srep30497"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dowall, S.D., Jacquot, F., Landon, J., Rayner, E., Hall, G., Carbonnelle, C., Raoul, H., Pannetier, D., Cameron, I., and Coxon, R. (2017). Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-03910-7"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dye, J.M., Wu, H., Hooper, J.W., Khurana, S., Kuehne, A.I., Coyle, E.M., Ortiz, R.A., Fuentes, S., Herbert, A.S., and Golding, H. (2016). Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Sci. Rep., 6.","DOI":"10.1038\/srep24897"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bounds, C.E., Kwilas, S.A., Kuehne, A.I., Brannan, J.M., Bakken, R.R., Dye, J.M., Hooper, J.W., Dupuy, L.C., Ellefsen, B., and Hannaman, D. (2015). Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal zaire and Sudan ebolaviruses. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137786"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.75.10.4649-4654.2001","article-title":"Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against","volume":"75","author":"Gupta","year":"2001","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1086\/520587","article-title":"Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates","volume":"196","author":"Jahrling","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_30","first-page":"182","article-title":"Issledovaniye provedeno rekombinantnykh belkov VP24 virusa Ebola na gumoral\u2019nyy otvet mononuklearnykh kletok morskikh svinok","volume":"6","author":"Shelemba","year":"2011","journal-title":"Acta Biomed. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiw333","article-title":"Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates","volume":"214","author":"Mire","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/cid\/civ680","article-title":"The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective from the Field","volume":"62","author":"Delamou","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1134\/S1068162022020169","article-title":"Monoclonal Antibodies for the Prevention and Treatment of Viral Infections","volume":"48","author":"Merkuleva","year":"2022","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1086\/514280","article-title":"Recombinant human monoclonal antibodies to Ebola virus","volume":"179","author":"Maruyama","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.virol.2010.02.029","article-title":"Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms","volume":"401","author":"Shedlock","year":"2010","journal-title":"Virology"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Oswald, W.B., Geisbert, T.W., Davis, K.J., Geisbert, J.B., Sullivan, N.J., Jahrling, P.B., Parren, P.W.H.I., and Burton, D.R. (2007). Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030009"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17182","DOI":"10.1073\/pnas.1414164111","article-title":"Structures of protective antibodies reveal sites of vulnerability on Ebola virus","volume":"111","author":"Murin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1128\/JVI.01490-15","article-title":"Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies","volume":"89","author":"Davidson","year":"2015","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/JVI.05549-11","article-title":"Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus","volume":"86","author":"Olal","year":"2012","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","article-title":"Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein","volume":"75","author":"Takada","year":"2001","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.vaccine.2006.09.076","article-title":"Protective efficacy of neutralizing antibodies against Ebola virus infection","volume":"25","author":"Takada","year":"2007","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Marzi, A., Yoshida, R., Miyamoto, H., Ishijima, M., Suzuki, Y., Higuchi, M., Matsuyama, Y., Igarashi, M., Nakayama, E., and Kuroda, M. (2012). Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036192"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies","volume":"141","author":"Qiu","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jviromet.2007.02.004","article-title":"Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens","volume":"143","author":"Shahhosseini","year":"2007","journal-title":"J. Virol. Methods"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Qiu, X., Fernando, L., Melito, P.L., Audet, J., Feldmann, H., Kobinger, G., Alimonti, J.B., and Jones, S.M. (2012). Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001575"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Audet, J., Wong, G., Wang, H., Lu, G., Gao, G.F., Kobinger, G., and Qiu, X. (2015). Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. Sci. Rep., 4.","DOI":"10.1038\/srep06881"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"JVI.00406-16","DOI":"10.1128\/JVI.00406-16","article-title":"Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry","volume":"90","author":"Tran","year":"2016","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nsmb.2150","article-title":"A shared structural solution for neutralizing ebolaviruses","volume":"18","author":"Dias","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1021\/cb5006454","article-title":"Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge","volume":"9","author":"Chen","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Frei, J.C., Nyakatura, E.K., Zak, S.E., Bakken, R.R., Chandran, K., Dye, J.M., and Lai, J.R. (2016). Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci. Rep., 6.","DOI":"10.1038\/srep19193"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Liu, Q., Fan, C., Li, Q., Zhou, S., Huang, W., Wang, L., Sun, C., Wang, M., Wu, X., and Ma, J. (2017). Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci. Rep., 7.","DOI":"10.1038\/srep45552"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Gui, M., Niu, X., He, S., Wang, R., Feng, Y., Kroeker, A., Zuo, Y., Wang, H., and Wang, Y. (2016). Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci. Rep., 6.","DOI":"10.1038\/srep25856"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","article-title":"Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization","volume":"52","author":"Gilchuk","year":"2020","journal-title":"Immunity"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"108984","DOI":"10.1016\/j.celrep.2021.108984","article-title":"Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies","volume":"35","author":"Murin","year":"2021","journal-title":"Cell Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e02154-15","DOI":"10.1128\/mBio.02154-15","article-title":"Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies","volume":"7","author":"Bornholdt","year":"2016","journal-title":"MBio"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","article-title":"Ansuvimab: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): An open-label phase 1 study","volume":"6736","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"6117","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_69","unstructured":"FDA (2018). Multi-Discipline Review, FDA. Inmazeb (Atoltivimab, Maftivimab, and Odesivimab-Ebgn) Application Number 761169Orig1s000."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: A randomised, first-in-human phase 1 study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.32607\/20758251-2015-7-4-11-21","article-title":"Broadly neutralizing antibodies against HIV-1 as a novel aspect of the immune response","volume":"7","author":"Shcherbakov","year":"2015","journal-title":"Acta Naturae"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","article-title":"Tackling influenza with broadly neutralizing antibodies","volume":"24","author":"Corti","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \u2018Trojan horse\u2019 bispecific-antibody strategy for broad protection against ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trivac.2014.04.002","article-title":"Novel neutralizing monoclonal antibodies protect rodents against lethal filovirus challenges","volume":"3","author":"Marceau","year":"2014","journal-title":"Trials Vaccinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1093\/infdis\/jiv209","article-title":"Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species","volume":"212","author":"Hernandez","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1093\/infdis\/jiv303","article-title":"Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP","volume":"212","author":"Reynard","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/JVI.02171-15","article-title":"Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses","volume":"90","author":"Holtsberg","year":"2016","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/JVI.02172-15","article-title":"Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein","volume":"90","author":"Keck","year":"2016","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","article-title":"Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site","volume":"15","author":"Howell","year":"2016","journal-title":"Cell Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Li","year":"2007","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability","volume":"169","author":"Zhao","year":"2017","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-018-08040-w","article-title":"Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates","volume":"10","author":"Brannan","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Furuyama, W., Marzi, A., Nanbo, A., Haddock, E., Maruyama, J., Miyamoto, H., Igarashi, M., Yoshida, R., Noyori, O., and Feldmann, H. (2016). Discovery of an antibody for pan-ebolavirus therapy. Sci. Rep., 6.","DOI":"10.1038\/srep20514"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pallesen, J., Murin, C.D., de Val, N., Cottrell, C.A., Hastie, K.M., Turner, H.L., Fusco, M.L., Flyak, A.I., Zeitlin, L., and Crowe, J.E. (2016). Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat. Microbiol., 1.","DOI":"10.1038\/nmicrobiol.2016.128"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.celrep.2018.08.009","article-title":"Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop Article Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop","volume":"24","author":"Murin","year":"2018","journal-title":"Cell Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"14701","DOI":"10.1073\/pnas.0606631103","article-title":"Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors","volume":"103","author":"Giritch","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.celrep.2015.08.038","article-title":"Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail","volume":"12","author":"Kugelman","year":"2015","journal-title":"Cell Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"199ra113","DOI":"10.1126\/scitranslmed.3006608","article-title":"Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail","volume":"5","author":"Pettitt","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"138ra81","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Qiu, X., Audet, J., Wong, G., Fernando, L., Bello, A., Pillet, S., Alimonti, J.B., and Kobinger, G.P. (2013). Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep., 3.","DOI":"10.1038\/srep03365"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1128\/JVI.00173-13","article-title":"Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs","volume":"87","author":"Qiu","year":"2013","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"207ra143","DOI":"10.1126\/scitranslmed.3006605","article-title":"mAbs and Ad-vectored IFN-\u03b1 therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms","volume":"5","author":"Qiu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/19420862.2015.1127492","article-title":"CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody","volume":"8","author":"Pettit","year":"2016","journal-title":"MAbs"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"PREVAIL II Writing Group & Multi-National PREVAIL II Study Team (2016). A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N. Engl. J. Med., 375, 1448\u20131456.","DOI":"10.1056\/NEJMoa1604330"},{"key":"ref_101","unstructured":"Aleem, A., and Kothadia, J.P. (2024, December 07). Remdesivir. StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563261\/."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"l5140","DOI":"10.1136\/bmj.l5140","article-title":"Two Ebola treatments halve deaths in trial in DRC outbreak","volume":"366","author":"Dyer","year":"2019","journal-title":"BMJ"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S2666-5247(22)00123-9","article-title":"Effects of therapies for Ebola virus disease: A systematic review and network meta-analysis","volume":"3","author":"Gao","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"329ra33","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mAb cocktail protects macaques against the Makona variant of Ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_106","first-page":"3","article-title":"China\u2019s response to the 2014\u20132016 Ebola crisis: Enhancing Africa \u2019 s soft security under Sino-US competition","volume":"35","author":"Cabestan","year":"2021","journal-title":"China Inf."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1038\/s41467-020-17446-4","article-title":"Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment","volume":"11","author":"Cross","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13543784.2021.1881061","article-title":"Expert Opinion on Investigational Drugs Targeting Ebola virus replication through pharmaceutical intervention","volume":"30","author":"Hansen","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.coviro.2022.101210","article-title":"The road to effective and accessible antibody therapies against Ebola virus","volume":"54","author":"Kobinger","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","article-title":"Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus","volume":"19","author":"Howell","year":"2017","journal-title":"Cell Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JVI.02151-09","article-title":"Biochemical and Structural Characterization of Cathepsin L-Processed Ebola Virus Glycoprotein: Implications for Viral Entry and Immunogenicity","volume":"84","author":"Hood","year":"2010","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.podrm.2022.11.003","article-title":"Remdesivir","volume":"48","author":"Bakheit","year":"2023","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/viro.2002.1533","article-title":"Detection of Antibodies against the Four Subtypes of Ebola Virus in Sera from Any Species Using a Novel Antibody-Phage Indicator Assay","volume":"300","author":"Meissner","year":"2002","journal-title":"Virology"},{"key":"ref_116","unstructured":"Zybkina, A.V. (2022). Psevdovirusy kak Instrumenty Izucheniya Poverkhnostnykh Glikoproteinov Filovirusov i Poiska Ingibitorov Proniknoveniya, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor. Available online: https:\/\/vector.make.st\/storage\/models\/referats\/10\/dzybkina.pdf."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/1\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:16Z","timestamp":1760028436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/1\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["antib14010022"],"URL":"https:\/\/doi.org\/10.3390\/antib14010022","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}